AffiliationInstitute for Cancer Studies, Christie Hospital, University of Manchester, Withington, Manchester, UK.
MetadataShow full item record
AbstractAngiogenesis has been validated as a target in ovarian cancer through four randomized trials that have reported improved progression-free survival (PFS) in patients with ovarian cancer whose conventional treatment was supplemented with concurrent and maintenance administration of the antivascular endothelial growth factor (VEGF) antibody, bevacizumab. These trials [the International Collaborative Ovarian Neoplasm Group trial (ICON7), the Gynecologic Oncology Group trial (GOG218), OCEANS and AURELIA] have shown that the tumour vasculature is a valid target throughout the lifetime of patients with ovarian cancer. This review seeks to address some of the remaining questions surrounding the optimal strategy for the use of bevacizumab in ovarian cancer.
CitationAngiogenesis as a target for the treatment of ovarian cancer. 2013, 25 (5):558-65 Curr Opin Oncol
JournalCurrent Opinion in Oncology
- Angiogenesis inhibitors for the treatment of ovarian cancer.
- Authors: Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J
- Issue date: 2011 Sep 7
- Bevacizumab in the treatment of ovarian cancer.
- Authors: Heitz F, Harter P, Barinoff J, Beutel B, Kannisto P, Grabowski JP, Heitz J, Kurzeder C, du Bois A
- Issue date: 2012 Sep
- Angiogenesis as a strategic target for ovarian cancer therapy.
- Authors: Spannuth WA, Sood AK, Coleman RL
- Issue date: 2008 Apr
- New ways to successfully target tumor vasculature in ovarian cancer.
- Authors: Yang X, Shen F, Hu W, Coleman RL, Sood AK
- Issue date: 2015 Feb
- The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
- Authors: Gubbi A, Kendrick JE, Finkler NJ
- Issue date: 2014 Oct